Get the Stockscreener App
10.29
0.06%
-0.0065
Voyager Acquisition Corp stock is traded at $10.29, with a volume of 255.87K.
It is down -0.06% in the last 24 hours and up +0.88% over the past month.
Voyager Acquisition Corp is a blank check company.
See More
Previous Close:
$10.30
Open:
$10.3
24h Volume:
255.87K
Relative Volume:
3.20
Market Cap:
$324.47M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.29%
1M Performance:
+0.88%
6M Performance:
+2.69%
1Y Performance:
+0.00%
1-Day Range:
$10.29
$10.30
1-Week Range:
$10.26
$10.30
52-Week Range:
$9.97
$11.20
Voyager Acquisition Corp Stock (VACH) Company Profile
Name
Voyager Acquisition Corp
Sector
Industry
Phone
03477204333
Address
C/O WINSTON & STRAWN LLP, HOUSTON
Compare VACH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VACH
Voyager Acquisition Corp
|
10.29 | 324.47M | 0 | 0 | 0 | 0.00 |
|
LION
Lionsgate Studios Corp
|
6.79 | 2.09B | 3.13B | 50.80M | 555.00M | 0.1772 |
|
AACT
Ares Acquisition Corporation Ii
|
11.26 | 696.54M | 0 | 16.92M | -1.35M | 0.29 |
|
ANSC
Agriculture Natural Solutions Acquisition Corp
|
10.72 | 461.01M | 0 | 1.30M | 0 | 0.0301 |
|
AAM
Aa Mission Acquisition Corp
|
10.31 | 453.59M | 0 | 0 | 0 | 0.00 |
|
EQV
Eqv Ventures Acquisition Corp
|
10.21 | 453.53M | 0 | 0 | 0 | 0.00 |
Voyager Acquisition Corp Stock (VACH) Latest News
Veraxa Biotech, OmniAb collaborate on bispecific ADC programme - World Pharmaceutical Frontiers
European de-SPAC M&A soars back — Dealspeak EMEA - ION Analytics
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program - GlobeNewswire Inc.
1,100,000 Shares in Voyager Acquisition Corp. (NASDAQ:VACH) Purchased by Aristeia Capital L.L.C. - MarketBeat
1,518,939 Shares in Voyager Acquisition Corp. (NASDAQ:VACH) Purchased by AQR Arbitrage LLC - MarketBeat
Berkley W R Corp Purchases New Shares in Voyager Acquisition Corp. (NASDAQ:VACH) - MarketBeat
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program - The Manila Times
Swiss biotech firm Veraxa to list on Nasdaq in $1.64 billion SPAC deal - MSN
Whitebox Advisors LLC Invests $1.50 Million in Voyager Acquisition Corp. (NASDAQ:VACH) - MarketBeat
Shaolin Capital Management LLC Buys New Position in Voyager Acquisition Corp. (NASDAQ:VACH) - MarketBeat
Veraxa to go public in $1.6bn SPAC deal with Voyager - MSN
Heights Capital Management Inc. Takes Position in Voyager Acquisition Corp. (NASDAQ:VACH) - MarketBeat
Duane Morris Represents Veraxa in $1.3 Billion SPAC Merger Agreement - Duane Morris LLP
Veraxa Biotech to go public via $1.64bn SPAC deal with Voyager Acquisition - World Pharmaceutical Frontiers
Switzerland: Voyager Acquisition Corp combines with Veraxa for Nasdaq IPO - Investors in Healthcare
One of the largest preclinical ADC deals: Taiho Pharma’s US$1.14bn acquisition of Araris Biotech - Investors in Healthcare
Sweden: Biotage recommends shareholders accept KKR’s SEK11.607bn public takeover offer - Investors in Healthcare
New Providence Acquisition Corp. III (NPACU) Prices $261M IPO - SPAC Insider
Voyager Acquisition Corp Inc. (VACH) Price Performance: The Role of Supply and Demand - investchronicle.com
Roku Inc (ROKU) Stock: From Low to High in 52 Weeks - investchronicle.com
Veraxa through a SPAC heads to Nasdaq - BioWorld MedTech
Astera Labs Inc (ALAB) Stock: A Year of Stock Market Dynamics - investchronicle.com
German antibody maker valued at $1.6B in blank-check merger - BioPharma Dive
Swiss ADC Biotech Takes SPAC Track to NASDAQ - BioSpace
Cancer drug developer Veraxa to list in US via $1.64B SPAC merger - FirstWord Pharma
Veraxa makes a SPAC deal; Illumina discloses layoffs - Endpoints News
Actinium Pharmaceuticals Inc (ATNM Stock: A Sea of Opportunity - investchronicle.com
Dynex Capital, Inc (DX) Stock: Navigating a Year of Volatility - investchronicle.com
Swiss Drug Developer Veraxa To List In US In $1.6B SPAC Deal - Law360
Veraxa to list on Nasdaq through Voyager Acquisition Corp merger - The Pharma Letter
Antero Resources Corp (AR) Stock: From Low to High in 52 Weeks - investchronicle.com
Vistra Corp (VST) Stock: Navigating a Year of Stock Volatility - investchronicle.com
HST’s Stock Market Puzzle: Piecing Together 2023’s Performance - investchronicle.com
IPO Radar: VERAXA, CATL and Zopa - The Armchair Trader
German cancer antibody biotech eyes SPAC as route to Nasdaq - Fierce Biotech
Voyager Acquisition, VERAXA Biotech to Merge, Creating $1.64 Billion Public Cancer Therapy Company - marketscreener.com
Xlife Sciences AG Says Veraxa Biotech AG To Merge With Voyager Acquisition Corp. - marketscreener.com
Xlife Sciences’ VERAXA Biotech to Merge with Voyager Acquisition Corp. - TipRanks
ForexTV | Small Business Resources - ForexTV
Corbion announces strong first quarter 2025 results, well on track to deliver full-year outlook - The Manila Times
VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination to Advance Next-Generation Cancer Therapies - Nasdaq
VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies - TradingView
Voyager Acquisition (NASDAQ:VACH) Trading Down 0.2%Here's Why - MarketBeat
Ireland: Investindustrial agrees acquisition of DCC’s healthcare division for £1.05bn - Investors in Healthcare
Voyager Acquisition (NASDAQ:VACH) Trading Down 0.2% – Time to Sell? - Defense World
Americas Technology Acquisition (NYSEARCA:ATA) Stock Passes Above 200-Day Moving Average – Here’s Why - Defense World
Spark I Acquisition (NASDAQ:SPKL) Stock Price Down 0.3% – Time to Sell? - Defense World
Lumina Gold Corp. (OTCMKTS:LMGDF) Short Interest Update - Defense World
AudioEye, Inc. (NASDAQ:AEYE) Receives Average Rating of “Buy” from Brokerages - Defense World
France: Mérieux Equity Partners sells stake in Theravia to Norgine - Investors in Healthcare
UK: Apposite Capital’s HCML acquires ILS - Investors in Healthcare
Voyager Acquisition Corp Stock (VACH) Financials Data
There is no financial data for Voyager Acquisition Corp (VACH). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
13.57%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):